What is PBM stock price today?

PBM (Psyence Biomedical Ltd) stock is trading at $7.60 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is PBM stock going up or down today?

PBM stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy PBM stock now?

The decision to buy PBM depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is PBM a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for PBM based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is PBM stock overvalued or undervalued?

Use our DCF valuation calculator to determine if PBM is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is PBM's P/E ratio?

P/E ratio data for PBM will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is PBM's market cap?

PBM (Psyence Biomedical Ltd) has a market capitalization of $0.02 billion, making it a small-cap stock.

What is PBM's price to book ratio?

PBM trades at a price-to-book (P/B) ratio of 1.46, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does PBM pay dividends?

PBM does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is PBM's dividend yield?

PBM does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is PBM stock a good long-term investment?

PBM's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is PBM's revenue growth rate?

Revenue growth data for PBM is available on our dashboard with detailed financial statement analysis.

Profitability metrics for PBM are available on our dashboard with complete income statement analysis.

What are the risks of investing in PBM?

Key risks for PBM include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does PBM compare to its competitors?

Compare PBM to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize PBM's performance and positioning.

What is PBM's stock price target for 2026?

Our AI model provides price targets for PBM based on fundamental analysis: Bull case $9.88 (+30%), Base case $8.74 (+15%), Bear case $6.84 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about PBM?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for PBM. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is PBM's next earnings report?

PBM reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

PBM - Psyence Biomedical Ltd

NYSE * Health Care * Biotechnology

$7.60

+$1.73 (+29.47%)

About Psyence Biomedical Ltd

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

PBM Key Statistics

Market Cap

$17.43M

P/B Ratio

1.46

EPS

$-389.98

Employees

How PBM Compares to Peers

PBM is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
PBM(This stock)	$17.43M	N/A	0%	0.0%	-
AMGNAmgen Inc	$191.53B	24.6	0%	0.2%	vs AMGN
GILDGilead Sciences	$170.84B	20.3	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$112.22B	28.8	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.35B	18.1	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.03B	20.0	-0%	0.1%	vs BIIB

Psyence Biomedical Ltd Company Information

Headquarters: Ontario; Canada
Website: www.psyencebiomed.com
Sector: Health Care
Industry: Biotechnology

About Psyence Biomedical Ltd

PBM Key Statistics

How PBM Compares to Peers

Psyence Biomedical Ltd Company Information

Upcoming Events for PBM